Cogent Biosciences, Inc.

Biomedtracker’s latest report on biopharmaceutical company fundraising shows a 25.1% decline in year-over-year dollars raised, from $17.5bn in the fourth quarter of 2022 to $13.1bn in Q4 of 2023. Foll

The American Society of Clinical Oncology annual meeting often is followed by several follow-on public offerings (FOPOs) by small- to mid-sized public biotech companies reporting positive data at the

Blueprint Medicines Corporation ’s presentation of full data from the Phase III PIONEER study of Ayvakit (avapritinib) in indolent systemic mastocytosis (ISM) bolsters the drug’s chances of winning ap

Blueprint Medicines Corporation ’s Phase III PIONEER trial data for Ayvakit (avapritinib) in indolent systemic mastocytosis (ISM) will likely prove sufficient for US Food and Drug Administration appro